HeartSciences Inc. (NASDAQ: HSCS) reported its fiscal third‑quarter 2026 results, showing no meaningful revenue as the company remains in a pre‑revenue commercialization phase. Cash and cash equivalents stood at $3.4 million as of January 31, 2026, while shareholders’ equity was $2.7 million. The company posted a nine‑month net loss of $6.4 million for the period ending January 31, 2026, reflecting continued investment in research, development, and general and administrative expenses.
Regulatory progress was highlighted as a key milestone. The MyoVista wavECG device was submitted to the U.S. Food and Drug Administration for 510(k) pre‑market clearance in December 2025, and the MyoVista Insights healthcare IT platform received a significant upgrade on March 13, 2026 that added new AI algorithms and improved interoperability with hospital systems. These steps move the company closer to generating subscription revenue from its AI‑enabled ECG platform.
Comparing to the prior quarter, the company reported revenue of $2.42 million and an earnings per share of –$0.85 for the fiscal second quarter 2026, and the nine‑month net loss of $6.4 million underscores the cash burn required to reach commercial viability. The lack of revenue in Q3 2026 is consistent with the company’s stated focus on building reference sites and securing regulatory approvals before revenue generation can begin.
Management emphasized the significance of these developments. CEO Andrew Simpson said, "We are making strong progress toward our 2026 objectives, including establishing reference sites, commencing revenue generation for MyoVista Insights, making AI algorithms available on the platform, and achieving best‑in‑class interoperability across hospital systems." He added, "The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone and advances our broader strategy to modernize ECG through the integration of artificial intelligence." Simpson also noted, "The past year marked a turning point for HeartSciences as we move closer to commercialization and revenues in calendar 2026, pending regulatory clearances." He further remarked, "Our MyoVista Insights software has the potential to radically enhance the clinical utility of the ECG, one of the most widely used diagnostic tools in medicine today," and that "AI‑ECG represents a once‑in‑a‑generation opportunity to modernize an entire industry."
Business implications are clear: the company remains a pre‑revenue entity with limited cash reserves, raising a going‑concern risk that could constrain future operations. The FDA submission and platform upgrade are tailwinds that could accelerate commercialization, but the company’s heavy R&D and G&A spend continue to drive losses. Investors will monitor the company’s ability to secure additional financing or achieve early revenue to sustain its growth trajectory.
No forward guidance was disclosed in the filing, so the company’s outlook remains uncertain beyond the current quarter’s financials.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.